Roche Pharmaceuticals Division

Roche Pharmaceuticals Division is the flagship operating segment of F. Hoffmann-La Roche AG, a Swiss multinational healthcare company founded on October 1, 1896, by visionary entrepreneur Fritz Hoffmann-La Roche in Basel, Switzerland. As the world's fifth-largest pharmaceutical company by revenue and the global leader in cancer treatments, the Pharmaceuticals Division generated CHF 46.2 billion ($52.45 billion) in sales during 2024, representing an 8% increase at constant exchange rates. The division employs over 15,000 people in Switzerland alone, with more than 1,800 dedicated scientists, clinicians, engineers, and technicians from almost 60 nations working at the Pharma Research & Early Development facility in Basel. Operating through strategic subsidiaries including the wholly-owned American biotechnology company Genentech and Japanese pharmaceutical company Chugai Pharmaceuticals, Roche focuses on six key therapeutic areas: oncology, neuroscience and rare diseases, cardiovascular and metabolic diseases, immunology, infectious diseases, and ophthalmology. Oncology remains the division's primary revenue driver, accounting for 43% of pharmaceutical sales, with breakthrough treatments including the HER2 franchise generating $10.1 billion annually, Tecentriq achieving CHF 3.77 billion in sales, and innovative therapies like Perjeta and Kadcyla leading global cancer care. The division's commitment to scientific excellence is demonstrated through its state-of-the-art Basel headquarters, featuring cutting-edge laboratory facilities housed in high-rise buildings that form a unique research complex. With a robust pipeline of personalized medicines and targeted therapies, Roche Pharmaceuticals Division continues to transform healthcare by developing treatments that address the most challenging diseases, while maintaining its position as the industry leader in oncology and expanding its presence in neurological disorders and cardiovascular-metabolic diseases to meet the anticipated global disease burden by 2035.